Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-06-19 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第二十次会议的事前认可意见与独立意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the independent directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding opinions on several board meeting agenda items, including approval of a capital increase by a subsidiary, a 2023 equity incentive plan draft, and the purchase of directors and officers liability insurance. It references compliance with company law, securities law, and stock exchange listing rules. The content is focused on board meeting matters and independent directors' opinions rather than financial results or detailed financial statements. The document length is 3313 characters, which is relatively short and consistent with a board/management announcement rather than a full report. There is no indication of financial statements or earnings data. Therefore, this document fits best under Board/Management Information (MANG), as it announces board meeting related opinions and approvals.
2023-06-19 Chinese
2023年股权激励计划首次授予激励对象名单
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the initial grant list of the 2023 equity incentive plan. It details the allocation of restricted stock to board members, senior management, and core employees, including specific share quantities and percentages. The document also includes procedural notes about the approval process and conditions for the incentive plan. There are no financial statements, earnings data, or regulatory certifications present. The content focuses on equity incentive allocation, which is a capital/financing activity related to share-based compensation. Given the nature of the announcement about equity incentive grants and the absence of financial report data, the document best fits the category of Capital/Financing Update (CAP). The document length is short (1913 characters), but it contains substantive information about the equity incentive plan rather than merely announcing a report publication or providing a certification, so it is not RPA or RNS.
2023-06-19 Chinese
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2023年股权激励计划之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2023 equity incentive plan of Sichuan Zitonggong Pharmaceutical Co., Ltd. It extensively discusses the legal compliance, procedures, and details of the equity incentive plan, including stock allocation, eligibility, and regulatory adherence. The document is not a financial report, earnings release, or announcement of voting results. It is a legal opinion specifically related to a capital/financing activity (equity incentive plan). Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed substantive content rather than a brief announcement or certification, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2023-06-19 Chinese
第三届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 20th meeting of the third board of directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to related announcements on the stock exchange platform. The content focuses on board decisions, employee recognition, capital increases, equity incentive plans, and insurance purchases for directors and senior management. There is no indication that this is a full annual report, audit report, earnings release, or other financial report. Instead, it is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length (4830 characters) and detailed meeting minutes support this classification rather than a brief announcement or a report publication notice.
2023-06-19 Chinese
关于对拟认定核心员工进行公示并征求意见的公告
Regulatory Filings Classification · 90% confidence The document is a public announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the nomination and public notice of proposed core employees. It includes a list of nominated core employees and invites company employees to submit objections during a specified public notice period. The document references a board meeting resolution and mentions compliance with the Beijing Stock Exchange listing rules. The content focuses on internal personnel nomination and public consultation rather than financial results, management changes, or regulatory filings. It is not a full report, financial statement, or management change announcement but rather a public notice related to employee nomination. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-06-19 Chinese
关于全资子公司对参股公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding its wholly-owned subsidiary's capital increase in an associated company and related party transaction. It includes detailed information about the investment, the board and independent directors' approval, the investment agreement, and the impact on the company. The document is a regulatory announcement about a financing-related transaction (capital increase in an associate) and related party disclosures. It does not contain financial statements or comprehensive financial reports but rather a disclosure of a specific capital investment transaction and related approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 5,192 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2023-06-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.